Australia - inglés - Department of Health (Therapeutic Goods Administration)

zimmer biomet pty ltd - 34195 - unicondylar knee prosthesis - the femoral component of a partial knee system. the femoral component is designed for cemented application. it has twin location pegs to ensure stable fixation and an outer profile that allows the bearing to track correctly in a higher flexion position than the original femoral design. the oxford partial knee is intended for use in individuals with osteoarthritis or avascular necrosis limited to the medial compartment of the knee and is intended to be implemented with bone cement.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

zimmer biomet pty ltd - 34195 - unicondylar knee prosthesis - the tibial component of a unicompartmental knee. this is an anatomical tray designed to maximise bone coverage of the medial compartment. separatetrays are supplied for left and right medial compartments. it has a tinbn coating to reduce the release of metallic ions. the oxford partial knee is intended for use in individuals with osteoarthritis or avascular necrosis limited to the medial compartment of the knee and is intended to be implanted with bone cement.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

zimmer biomet pty ltd - 34195 - unicondylar knee prosthesis - cast cobalt chrome mo alloy for strength, wear resistance and biocompatibility. available in 5 sizes; parametric with the following radii of curvature: extra small 20mm; small 22mm; medium 24mm; large 26mm; extra large 28mm. the articulating surface is spherical and polished to a very high tolerance. the appropriate size of femoral component is chosen preoperatively by overlaying templates on a lateral radiograph of the knee. the oxford partial knee single peg cemented femoral is intended for partial replacement of the articulating surfaces of the knee when only one side of the knee joint is affected due to compartmental primary degenerative or post-traumatic degenerative disease, previous tibial condyle or plateau fractures, deformity or revision of previous partial arthroplasty in the affected compartment. oxford femoral components are indicated for use in the lateral compartment for a fixed bearing application. they are intended to be implanted with bone cement. oxford femoral components are also indicated for use in the medial compartment for a mobile bearing application. for mobile bearing articulation in the medial compartment with the oxford femoral component, please see additional instructions for use packaged with the mobile bearing and tibial implants. oxford femoral components are indicated for use with the domed lateral mobile bearings and tibial trays in the lateral compartment of the knee.

Filipinas - inglés - FDA (Food And Drug Administration)

n/a; importer: oxford distributions incorporated; distributor: oxford distributions incorporated - paracetamol , phenylpropanolamine (as hydrochloride), chlorphenamine maleate - capsule - 325mg/25mg/2mg

Filipinas - inglés - FDA (Food And Drug Administration)

raptakos brett & co. ltd.; distributor: oxford distributions incorporated - calcium carbonate , cholecalciferol (vit. d3) - effervescent granules for solution - 2.5 g / 400 iu

Filipinas - inglés - FDA (Food And Drug Administration)

raptakos brett & co. ltd; distributor: oxford distributions incorporated - clopidogrel - film coated tablets - 75 mg

Filipinas - inglés - FDA (Food And Drug Administration)

raptakos brett & co. ltd.; distributor: oxford distributions incorporated unit x - clopidogrel - film-coated tablet - 75 mg

Filipinas - inglés - FDA (Food And Drug Administration)

raptakos brett & co. ltd.; distributor: oxford distributions incorporated - salbutamol (as sulfate) - controlled release capsule - 4 mg

Filipinas - inglés - FDA (Food And Drug Administration)

raptakos brett & co.ltd; distributor: oxford distributions incorporated - calcium carbonate / cholecalciferol (vitamin d3) - effervescent granules for solution - 2.5g / 400 iu

Estados Unidos - inglés - NLM (National Library of Medicine)

oxford pharmaceuticals, llc - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - depression -for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. childhood enuresis -may be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. in patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. the effectiveness of treatment may decrease with continued drug administration. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute imipramine hydrochloride in patients receiving a monoamine oxidase inhibitor, as long an